COMET results are not stellar

The Lancet

Volumn 372, Issue 9652, 2008, Pages 1807-1808

  James, Michael ^a   Cleland, Les ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; METHOTREXATE; SALAZOSULFAPYRIDINE;

CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST BENEFIT ANALYSIS; DRUG COST; EVIDENCE BASED PRACTICE; HUMAN; LETTER; MEDICAL ETHICS; MONOTHERAPY; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

EID: 56249140474     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61755-9     Document Type: Letter

References (4)

1. Emery P., Breedveld F.C., Hall S., et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372 (2008) 375-382
2. Grigor C., Capell H., Stirling A., et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364 (2004) 263-269
3. Mottonen T., Hannonen P., Leirisalo-Repo M., et al., for the FIN-RACo trial group. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet 353 (1999) 1568-1573
4. Proudman S.M., Keen H.I., Stamp L.K., et al. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use. Semin Arthritis Rheum 37 (2007) 99-111